1) NeuVax decreased recurrence by nearly 80% in targeted group.
2) NeuVax's targeted group is twice the size of Herceptin's group
3) Herceptin did revenue of $7 billion in last 12 months
4) GALE has market cap of $200 million
5) INSY has created gains of 500% in the last year with the success of its fentanyl product Subsys
6) INSY product is near identical to Abstral, but Abstral works faster
7) GALE could triple on success from Abstral
8) GALE worth $600million on success of Abstral and $15 billion on success of NeuVax.
One more thing, what do you do with the Insy bottle...not convenient. Says you should spray out the remaining residue (fentanyl), place in bag provided, then throw in trash...can't believe environmentalist will like that one!!! Oh, where do you safely discard the remaining residue? Oh, down the drain, wow, there goes the water again!!!